Cavernous auto-injection therapy with prostaglandin E1

Area of Science:

• Urology
• Andrology
• Pharmacology

Background:

• Erectile dysfunction (ED) affects a significant number of men, impacting quality of life.
• Various treatment modalities exist, but patient acceptance and long-term adherence remain challenges.
• Pharmacological interventions, including prostaglandin E1, offer potential therapeutic options.

Purpose of the Study:

• To evaluate the efficacy and safety of cavernous auto-injection therapy using prostaglandin E1 for erectile dysfunction.
• To assess patient acceptance and adherence rates for this treatment modality.
• To determine the overall success rate of prostaglandin E1 auto-injections in achieving adequate erections for sexual intercourse.

Main Methods:

• Prospective investigation of 176 consecutive male patients with erectile dysfunction (aged 18-83 years).
• Pharmacological testing with prostaglandin E1 (20 micrograms) was administered to assess response.
• Auto-injection therapy with prostaglandin E1 was offered as a primary treatment to 131 patients.

Main Results:

• Pharmacological testing with prostaglandin E1 was positive in 64% of patients tested.
• Auto-injection therapy was initiated by 76% of eligible patients, with 74% continuing after three months.
• The overall efficacy of prostaglandin E1 to induce adequate erections for sexual intercourse was estimated at 71%.

Conclusions:

• Cavernous auto-injection therapy with prostaglandin E1 is a well-accepted, effective, and safe treatment for both psychogenic and organic erectile dysfunction.
• The therapy demonstrates high patient adherence and a favorable efficacy rate.
• All patients with erectile dysfunction should be informed about this treatment option.